Literature DB >> 23605648

Chemoprevention of gastrointestinal neoplasia.

Elizabeth Half1, Nadir Arber.   

Abstract

Cancer chemoprevention is defined as the pharmacologic intervention, by drugs or nutrient-components, with the process of carcinogenesis, in order to prevent the development of invasive malignant neoplasms. This preventive attempt is particularly challenging in cancer types, which have a long subclinical developmental phase, because of their low cellular proliferation rate and their slow pre-clinical evolution, until they become clinically detectable and therapeutically as well as prognostically relevant. Therefore, only certain specific cancer types are presently in the focus of clinical chemoprevention. Among the GI tract cancer, colorectal (CRC) as well as esophageal cancer have raised the most attention over the past decades, as they both share a long precancerous stage (the adenoma in CRC and Barrett's esophagus in the case of esophageal adenocarcinoma) which provides a window of opportunity to intervene and prevent development of cancer.In this review, we will focus on both CRC as well as esophageal adenocarcinoma (EAC).

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23605648     DOI: 10.1007/s11894-013-0320-x

Source DB:  PubMed          Journal:  Curr Gastroenterol Rep        ISSN: 1522-8037


  53 in total

Review 1.  The role of low-dose aspirin in the prevention of colorectal cancer.

Authors:  Doran Avivi; Menachem Moshkowitz; Elmar Detering; Nadir Arber
Journal:  Expert Opin Ther Targets       Date:  2012-02-08       Impact factor: 6.902

2.  American Gastroenterological Association medical position statement on the management of Barrett's esophagus.

Authors:  Stuart J Spechler; Prateek Sharma; Rhonda F Souza; John M Inadomi; Nicholas J Shaheen
Journal:  Gastroenterology       Date:  2011-03       Impact factor: 22.682

3.  Host and pathogen factors for Clostridium difficile infection and colonization.

Authors:  Vivian G Loo; Anne-Marie Bourgault; Louise Poirier; François Lamothe; Sophie Michaud; Nathalie Turgeon; Baldwin Toye; Axelle Beaudoin; Eric H Frost; Rodica Gilca; Paul Brassard; Nandini Dendukuri; Claire Béliveau; Matthew Oughton; Ivan Brukner; Andre Dascal
Journal:  N Engl J Med       Date:  2011-11-03       Impact factor: 91.245

4.  Nonsteroidal anti-inflammatory drugs and statins have chemopreventative effects in patients with Barrett's esophagus.

Authors:  Florine Kastelein; Manon C W Spaander; Katharina Biermann; Ewout W Steyerberg; Ernst J Kuipers; Marco J Bruno
Journal:  Gastroenterology       Date:  2011-08-28       Impact factor: 22.682

5.  Surveillance and survival in Barrett's adenocarcinomas: a population-based study.

Authors:  Douglas A Corley; Theodore R Levin; Laurel A Habel; Noel S Weiss; Patricia A Buffler
Journal:  Gastroenterology       Date:  2002-03       Impact factor: 22.682

6.  Epidemiological differences between adenocarcinoma of the oesophagus and adenocarcinoma of the gastric cardia in the USA.

Authors:  H B El-Serag; A C Mason; N Petersen; C R Key
Journal:  Gut       Date:  2002-03       Impact factor: 23.059

Review 7.  Preclinical efficacy evaluation of potential chemopreventive agents in animal carcinogenesis models: methods and results from the NCI Chemoprevention Drug Development Program.

Authors:  V E Steele; R C Moon; R A Lubet; C J Grubbs; B S Reddy; M Wargovich; D L McCormick; M A Pereira; J A Crowell; D Bagheri
Journal:  J Cell Biochem Suppl       Date:  1994

Review 8.  Statins are associated with reduced risk of esophageal cancer, particularly in patients with Barrett's esophagus: a systematic review and meta-analysis.

Authors:  Siddharth Singh; Abha Goyal Singh; Preet Paul Singh; Mohammad Hassan Murad; Prasad G Iyer
Journal:  Clin Gastroenterol Hepatol       Date:  2013-01-26       Impact factor: 11.382

9.  Regular statin and aspirin use in patients with Barrett's oesophagus is associated with a reduced incidence of oesophageal adenocarcinoma.

Authors:  Ian L P Beales; Inna Vardi; Leanne Dearman
Journal:  Eur J Gastroenterol Hepatol       Date:  2012-08       Impact factor: 2.566

10.  A combination of esomeprazole and aspirin reduces tissue concentrations of prostaglandin E(2) in patients with Barrett's esophagus.

Authors:  Gary W Falk; Navtej S Buttar; Nathan R Foster; Katie L Allen Ziegler; Catherine J Demars; Yvonne Romero; Norman E Marcon; Thomas Schnell; Douglas A Corley; Prateek Sharma; Marcia R Cruz-Correa; Chin Hur; David E Fleischer; Amitabh Chak; Kenneth R Devault; David S Weinberg; Gary Della'Zanna; Ellen Richmond; Thomas C Smyrk; Sumithra J Mandrekar; Paul J Limburg
Journal:  Gastroenterology       Date:  2012-07-11       Impact factor: 22.682

View more
  2 in total

Review 1.  Chemoprevention in gastrointestinal physiology and disease. Targeting the progression of cancer with natural products: a focus on gastrointestinal cancer.

Authors:  Roxane Khoogar; Byung-Chang Kim; Jay Morris; Michael J Wargovich
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2016-02-18       Impact factor: 4.052

Review 2.  Chemoprevention in gastrointestinal physiology and disease. Anti-inflammatory approaches for colorectal cancer chemoprevention.

Authors:  Alexandra M Fajardo; Gary A Piazza
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2015-05-28       Impact factor: 4.052

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.